We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-0.32%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$417M
Cap. Flow
-$194M
Cap. Flow %
-20.04%
Top 10 Hldgs %
49.08%
Holding
83
New
26
Increased
6
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$39.6M
2
VTYX
Ventyx Biosciences
VTYX
+$34.6M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$23.2M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.3M
5
ALGS icon
Aligos Therapeutics
ALGS
+$16.8M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$62.9M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$41.7M
3
NKTX icon
Nkarta
NKTX
+$35.5M
4
CMPS
Compass Pathways
CMPS
+$35M
5
BCYC
Bicycle Therapeutics
BCYC
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$280M
$62.5M 6.44%
2,906,352
-250,629
-8% -$10.8M
CYTK icon
2
Cytokinetics
CYTK
$10.9B
$60.4M 6.23%
1,325,000
+325,000
+33% +$12.5M
DSGN icon
3
Design Therapeutics
DSGN
$748M
$59.4M 6.12%
2,772,501
– –
BCYC
4
Bicycle Therapeutics
BCYC
$275M
$53M 5.46%
870,000
-605,000
-41% -$33.4M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$47.3M 4.88%
1,000,000
-450,000
-31% -$17.7M
DICE
6
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$42.1M 4.34%
1,664,251
+504,000
+43% +$14.8M
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$39.3M 4.05%
300,000
-160,000
-35% -$20.7M
DYN icon
8
Dyne Therapeutics
DYN
$4.19B
$38.5M 3.97%
3,234,392
-385,000
-11% -$5.41M
ALGS icon
9
Aligos Therapeutics
ALGS
$26.3M
$36.9M 3.81%
124,511
+46,000
+59% +$16.8M
IDYA icon
10
IDEAYA Biosciences
IDYA
$3.5B
$36.6M 3.78%
1,550,000
-225,000
-13% -$5.23M
VTYX
11
DELISTED
Ventyx Biosciences
VTYX
$36.2M 3.74%
+1,824,280
New +$34.6M
RPTX
12
DELISTED
Repare Therapeutics
RPTX
$35.9M 3.7%
1,700,000
+1,680,000
+8,400% +$39.6M
OLMA icon
13
Olema Pharmaceuticals
OLMA
$1.07B
$35M 3.61%
3,743,875
– –
KZR
14
DELISTED
Kezar Life Sciences
KZR
$24.2M 2.5%
145,000
-265,000
-65% -$29.9M
FMTX
15
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$22.8M 2.35%
1,600,000
-515,000
-24% -$8.91M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$22M 2.26%
+750,000
New +$23.2M
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$21.7M 2.24%
+1,300,000
New +$21.3M
LONA
18
LeonaBio Inc
LONA
$69.6M
$21.2M 2.19%
163,074
-22,507
-12% -$2.85M
VERV
19
DELISTED
Verve Therapeutics
VERV
$16.3M 1.69%
443,265
– –
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.5M 1.6%
1,120,000
+695,000
+164% +$8.61M
HARP
21
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$14.6M 1.5%
+193,000
New +$13.2M
EWTX icon
22
Edgewise Therapeutics
EWTX
$4.45B
$13M 1.34%
850,000
+168,188
+25% +$3.03M
KYMR icon
23
Kymera Therapeutics
KYMR
$9.18B
$12.7M 1.31%
+200,000
New +$11.6M
EPIX
24
DELISTED
ESSA Pharma
EPIX
$12.3M 1.27%
865,000
-135,000
-14% -$1.5M
FULC icon
25
Fulcrum Therapeutics
FULC
$251M
$12.1M 1.25%
+685,000
New +$13.6M
1
2 3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2021 Portfolio in Review

As of Q4 2021, Logos Global Management held 83 positions worth $970M, down 30% from $1.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Logos Global Management withdrew a net $194M in Q4 2021, closing 17 positions and reducing 23 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $62.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Ventyx Biosciences worth $36.2M.

  • Logos Global Management's largest Q4 2021 buy was Ventyx Biosciences: 1,824,280 shares worth $36.2M.
  • Logos Global Management added most to Repare Therapeutics in Q4 2021, an estimated $39.6M increase.
  • Logos Global Management's biggest Q4 2021 reduction was Compass Pathways, cutting an estimated $35M.
  • Logos Global Management fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, selling an estimated $62.9M.
  • Logos Global Management's ten largest holdings make up 49% of its $970M portfolio in Q4 2021.
  • Logos Global Management opened 26 new positions and closed 17 in Q4 2021.
  • Logos Global Management's portfolio value fell 30% quarter-over-quarter to $970M.

Based on Logos Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.